US Stock MarketDetailed Quotes

CTSO Cytosorbents

Watchlist

1.010
+0.119+13.36%

Close Dec 13 16:00 ET

1.010
0.000-0.01%

Post 20:01 ET

55.38MMarket Cap-2.81P/E (TTM)

Cytosorbents Stock Forum

Jaguar8

Nov 11 06:30

NEWS

$Cytosorbents (CTSO.US)$
CytoSorbents And Converge Biotech Announce Strategic Partnership to Expand Sepsis and Critical Care Treatment with CytoSorb in India
CytoSorbents (NASDAQ: CTSO) and Converge Biotech have announced a strategic partnership to expand their market reach in India's sepsis and critical care markets. CytoSorbents' flagship product, CytoSorb, a blood purification technology that reduces cytokine storm and inflammatory toxins, will be distributed through Converge Biotech's ext...

Stock_Drift

Oct 1 04:35

10/1/24 Pre_Market Ticks, 5:33am est.

$Kaixin Holdings (KXIN.US)$ $Cytosorbents (CTSO.US)$ $MicroCloud Hologram (HOLO.US)$ $Bionomics (BNOX.US)$ $Tuniu (TOUR.US)$ $ZK International (ZKIN.US)$ $SHINECO (SISI.US)$ $XChange TEC (XHG.US)$ $SITE Centers (SITC.US)$ $AgEagle Aerial Systems (UAVS.US)$

Mcsnacks H Tupack

Jul 29 14:38

Broke resistance

$Cytosorbents (CTSO.US)$ It can run from here.

Jaguar8

May 2 06:08

$Cytosorbents (CTSO.US)$
NEWS
CytoSorbents May 6, 2024 Virtual KOL and Analyst-Investor Day: STAR-T Pivotal Trial Topline Results & Real World Experience with Antithrombotic Drug Removal in Europe

Moomoo AI

Dec 28, 2023 13:41

Despite promising growth forecasts, investor sentiment appears reserved, as revealed in the company's P/S ratio. Additionally, the recent stock price surge didn't significantly affect the P/S ratio, implying tempered revenue expectations. The high-growth yet low P/S ratio raises caution in market.